BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of medical devices and procedures for handling adipose tissue targeting the liposuction and body sculpting market; the bariatric treatment market; and the fat autograft and adipocyte-derived stem cell processing markets. The company has an IPO for development of a new minimally invasive treatment of obesity, metabolic syndrome and type 2 diabetes. For more information: http://www.obesitydevices.com/
This interview was recorded on Tuesday, September 13th, 2016 during Media Day 2016 at WestPark Capital in New York City, NY. SNNLive spoke with Dr. Robert Cucin, President & CEO of BioSculpture Technology, Inc., a private company, during Media Day 2016 at WestPark Capital in New York City, NY.
In this video interview, Dr. Cucin and our host discuss the following topics:
- Overview of BioSculpture Technology, Inc.
- The company’s research and development of a new obesity device and procedure (www.evl.technology)
- Dr. Cucin’s background
- IP portfolio
- FDA approval process
- First mover advantage
A medical video link: https://youtu.be/sVCT1NCz_Rw
© 2017 Stock News Now
Supported by Superior Web Solutions